metabolic syndrome. Metabolic syndrome
Conditions
Interventions
Intervention 1: First intervention group: Synbiotic recipients who receive two synbiotic supplements daily for 8 weeks. The synbiotic consumed is the FamiLact2plus supplement from Zist-Takhmir Company
Sponsors
Gorgan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
30 Years to 55 Years
Inclusion criteria
Inclusion criteria: Adults With a diagnosis of metabolic syndrome
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Diversity, composition of gut microbiota in stool samples (using Shannon index to estimate alpha diversity; and using UniFrac index (Unweighted and Weighted) to obtain Beta Diversity) ABSI was also measured as an index that combines information on waist circumference, weight, and height, and higher values ??indicate that the person has a higher waist circumference in relation to his height and weight and are associated with higher abdominal obesity. On the other hand, ABSI is a complementary index to BMI for assessing the risk of chronic diseases and a more suitable index than other anthropometric methods for predicting mortality. In general, anthropometric data, including weight (with an accuracy of 100 grams), height, and waist and hip circumference (using a non-elastic tape measure with an accuracy of 1 mm) were measured using standard methods. The WHR index was obtained by dividing the waist circumference by the hip circumference. The A Body Shape Index was calculated based on the following formula: ABSI = The following formulas were used to calculate the LAP and VAI factors: LAP = WC-65 * TG, in males LAP = WC-58 * TG, in females VAI= (WC/39.68 + 1.88 * BMI) *(TG/1.03) *(1.31/HDL), in males VAI= (WC/36.58 + 1.89 * BMI) *(TG/0.81) *(1.52/HDL), in females. Timepoint: Before and after the intervention (at the beginning and two months later). Method of measurement: Fecal microbiome sequencing DNA isolation and microbiome sequencing of fecal samples will be performed using Realtime PCR technique. Fecal microbiome analysis Diversity criteria include: Alpha diversity: richness (number of species) and evenness (distribution of species) will be assessed using indices such as Shannon index and Simpson index. Beta diversity: relationships between different samples will be analyzed using molecular analysis of variance (PCoA) and AMOVA will be used. Composition criteria Firmicutes-to-Bacteroidetes Ratio (F/B Ratio) will be | — |
Secondary
| Measure | Time frame |
|---|---|
| Plasma levels of gut-derived metabolites (e.g., SCFAs, TMAO). Measurement of metabolic factors will be used to assess the functional capacity of the gut microbiota. Metabolic analyses include short-chain fatty acids (SCFAs): butyrate, acetate, propionate. Trimethylamine-N-oxide (TMAO): associated with cardiovascular risk. and lipopolysaccharide (LPS): a marker of intestinal permeability and inflammation. Timepoint: Before and two months later. Method of measurement: Stool and blood samples will be collected at baseline and after 8 weeks. Samples will be processed and stored at -80°C until analysis. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMotahareh Hasani
Gorgan University of Medical Sciences
Outcome results
None listed